期刊名称：NANOTOXICOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Nanotoxicology invites contributions addressing research relating to the potential for human and environmental exposure, hazard and risk associated with the use and development of nano-structured materials. In this context, the term nano-structured materials has a broad definition, including materials with at least one dimension in the nanometer size range? These nanomaterials range from nanoparticles and nanomedicines, to nano-surfaces of larger materials and composite materials. The range of nanomaterials in use and under development is extremely diverse, so this journal includes a range of materials generated for purposeful delivery into the body (food, medicines, diagnostics and prosthetics), to consumer products (e.g. paints, cosmetics, electronics and clothing), and particles designed for environmental applications (e.g. remediation). It is the nano-size range if these materials which unifies them and defines the scope of Nanotoxicology.
While the term toxicology indicates risk, the journal Nanotoxicology also aims to encompass studies that enhance safety during the production, use and disposal of nanomaterials. Well-controlled studies demonstrating a lack of exposure, hazard or risk associated with nanomaterials, or studies aiming to improve biocompatibility are welcomed and encouraged, as such studies will lead to an advancement of nanotechnology. Furthermore, many nanoparticles are developed with the intention to improve human health (e.g. antimicrobial agents), and again, such articles are encouraged. In order to promote quality, Nanotoxicology will prioritise publications that have demonstrated characterisation of the nanomaterials investigated.
Nanotoxicology publishes WebFirst. WebFirst is a method of publishing where a journal is made available as multiple online issues throughout the year, with a single print archive copy of the entire volume being published at the end of the year. Access to the online version is included in all subscriptions.
Abstracting & Indexing
Nanotoxicology is currently indexed in: Biochemistry & Biophysics Citation Index; Biological Abstracts; BIOSIS Previews; Current Contents/Agriculture, Biology, and Environmental Sciences; Current Contents/Life Sciences; Current Contents/Social and Behavioral Sciences; Journal Citation Reports/Science Edition.
Instructions to Authors
Submission of Manuscripts
All submissions should be made online at Nanotoxicology�/I> Manuscript Central site. New users should first create an account. Once a user is logged onto the site submissions should be made via the Author Centre.
Please submit the main text, together with the legends to figures and any tables, in a single file in Word for Windows (PC) format. (Manuscripts and figures that are submitted in PDF format cannot be processed for publication.) Figures for the main text, appropriately numbered but without legends, should be submitted in a PowerPoint, TIFF, or JPG file. Supplementary text, legends to supplementary figures and supplementary tables, should be submitted in an additional, single file in Word format. Supplementary figures should be submitted in a separate PowerPoint, TIFF, or JPG file. For Supplementary movie files, please see below.
Preparation of Manuscripts Nanotoxicology considers all manuscripts on the strict condition that they have been submitted only to Nanotoxicology, that they have not been published already, nor are they under consideration for publication or in press elsewhere. Authors who fail to adhere to this condition will be charged with all costs that Nanotoxicology incurs and their papers will not be published.
Manuscripts that provide physical and chemical characterisation of the nanomaterials tested, either directly, or by referencing previous publications using the same batch of material, will be prioritised for publication.
Research article contributions to Nanotoxicology must report original research and all manuscripts will be subjected to review by referees. The following guidelines apply:
- Manuscripts should be compiled in the following order: title page; abstract; keywords; main text (introduction, methods, results and discussion); acknowledgments; appendixes (as appropriate); references; table(s) with caption(s) (on individual sheets); figure caption(s) (as a list).
- All the authors of a paper should include their full names, affiliations, postal addresses, telephone and fax numbers and email addresses on the cover page of manuscripts.
- Abstracts of 100-150 words are required for all papers submitted and should precede the text of a paper - see Notes on Style.
- Each paper should have two to five keywords.
- Results and Discussion must be written as separate discrete sections, not combined.
- For all manuscripts non-discriminatory language is mandatory. Sexist or racist terms should not be used.
- Manuscripts for hard-copy submission should be typed on single sides of good quality white A4 or 8 x 11 inch paper, double-spaced throughout including the reference section, with wide (3 cm) margins.
- Section headings should be concise and numbered sequentially, using a decimal system for subsections.
- Papers are accepted only in English
- Authors must adhere to SI Units.
- For information on submitting animations, movie files and sound files or any additional information including indexes and calendars please click here.
- When using a word which is or is asserted to be a proprietary term or trade mark authors must use the symbol ® or �or alternatively a footnote can be inserted using the wording below:
This article includes a word that is or is asserted to be a proprietary term or trade mark. Its inclusion does not imply it has acquired for legal purposes a non-proprietary or general significance, nor is any other judgement implied concerning its legal status.
- For further information, including referencing style, please visit Notes on Style.
Ethics and Consent
When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. Do not use patients�names, initials, or hospital numbers, especially in illustrative material. Papers including animal experiments or clinical trials must be conducted with approval by the local animal care or human subject committees, respectively.
Identifying information should not be published in written descriptions, photographs, and pedigrees, unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published
Disclosure of Potential Conflicts of Interest
It is the policy of all Informa Healthcare to adhere to the Conflict of Interest policy recommended by the ICMJE. It is the sole responsibility of authors to disclose any affiliation with any organisation with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, employment, expert testimony, honoraria, speakers’bureaus, retainers, stock options or ownership) that may affect the conduct or reporting of the work submitted. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure. Information about potential conflict of interest should be clearly stated at the point of submission (for example in a cover letter, or where available within the appropriate field on the journal�Manuscript Central site). This may be made available to reviewers and may be published with the manuscript at the discretion of the Editors.
Disclosure of Sources of funding
All sources of funding for research are to be explicitly stated, at the point of submission. This may be published with the manuscript at the discretion of the Editors.
Authorship Contributions
Contributions must be substantial in order to warrant authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. All other contributors should be listed as acknowledgements.
Colour Charges
Any figure submitted as a colour original will appear in colour in the Journal’s online edition free of charge and can be downloaded. Paper copy colour reproduction will only be considered on condition that authors contribute to the associated costs. The charges are £500/US$1010 for the first colour page and £250/US$515 for each colour page after per article.
There are no charges for non-colour pages.
Proofs
The Editor reserves the right to proceed to press without submitting page proofs to the author. However, usual practice will involve corresponding authors receiving email notification with a password and Web address from which to download a PDF. Hard copies of proofs will not be mailed. To avoid delays in publication, corrections to proofs must be returned within 48 hours, by electronic transmittal, fax or mail. Authors will be charged for excessive correction at this stage of production.
If authors do not return page proofs promptly, the Editor reserves the choice to either delay publication to a subsequent issue or to proceed to press without author corrections.
Offprints and Reprints
Free article access: Corresponding authors will receive free online access to their article through our website (www.informahealthcare.com). Reprints of articles published in Nanotoxicology can be purchased through Rightslink® when proofs are received. If you have any queries, please contact our reprints department at jenn.kane@informausa.com.
Copyright
It is a condition of publication that authors assign copyright or license the publication rights in their articles, including abstracts, to Informa UK Ltd. This enables us to ensure full copyright protection and to disseminate the article, and the Journal, to the widest possible readership in print and electronic formats as appropriate. Authors may, of course, use the article elsewhere after publication without prior permission from Informa UK Ltd., provided that acknowledgement is given to the Journal as the original source of publication, and that Informa Healthcare is notified so that our records show that its use is properly authorised. Authors retain a number of other rights under the Informa UK Ltd. rights policies documents.
Authors are themselves responsible for obtaining permission to reproduce copyright material from other sources.
A copyright agreement form can be downloaded by corresponding authors of accepted manuscripts with proofs. This should be signed and returned to Informa Healthcare.
For more information, please see Author Resources.
NIH Public Access Policy
In consideration of the National Institutes of Health (NIH) Public Access Policy, Informa Healthcare acknowledges that the broad and open dissemination of NIH-funded research results may benefit future scientific and medical research. Because we value the current and future contributions our journals make to the scientific body of knowledge, we have made certain that our policies accommodate those authors who wish to submit to PubMed Central.
Informa Healthcare's position with respect to public access to NIH-funded work published in Informa Healthcare journals is as follows:
- Informa Healthcare will deposit funded work to PubMed Central/UK PubMed Central for public access posting 12 months (NIH) or 6 months (Wellcome Trust) after final publication in electronic form.
- “Funded work�shall be defined as the final, peer-reviewed manuscript that is accepted by the Editor in Chief of the journal. This manuscript must not be altered by Publisher's copyediting and typesetting services.
- This embargo period begins the day the work is published online at www.informahealthcare.com.
Contacting the Publisher
Nanotoxicology
Informa Healthcare
5th Floor
Telephone House
69-77 Paul Street
London
EC2A 4LQ, UK
Tel: (+44) 207 017 4303
Fax: (+44) 207 017 6914
Email us here (Please include Journal name in all correspondence.)
Editorial Board
Interim Editor in Chief: Dr. Alison Elder - University of Rochester, Rochester, NY, USA
Editor at Large:
Prof. Vicki Stone - Edinburgh Napier University, Edinburgh, USA
Associate Editors:
Dr. Mark Weisner - Duke University, USA
Dr. Steve Roberts - University of Florida, USA
Editorial Board:
Prof. Marc Benedetti - Université Denis Diderot, Paris, France
Dr. Pratim Biswas - Washington University in St Louis, USA
Prof. Paul Borm - Hogeschool Zuyd, Heerlen, The Netherlands
Dr. Fanqing Frank Chen - Lawrence Berkeley National Laboratory, USA
Prof. Vicki Colvin - Rice University, Houston, US
Prof. Ken Donaldson - University of Edinburgh, UK
Dr. Steve Klaine - Clemson University, USA
Prof. Dr. Jorg Kreuter - Johann Wolfgang-Goethe-Universitaet, Germany
Dr. Wolfgang Kreyling - Institute for Inhalation Biology, Germany
Dr. Andrew Maynard - Woodrow Wilson International Center for Scholars, USA
Dr. Nancy Monteiro-Riviere - North Carolina State University, USA
Dr. Yasuo Morimoto - University of Occupational and Environmental Health, Kitakyushu, Japan
Prof. Günter Oberdörster - University of Rochester, USA
Prof. Wolfgang J. Parak - Philipps Universität, Germany
Dr. Enrico Sabbioni - University of Chieti, Italy
Dr. Lang Tran - Institute of Occupational Medicine, UK
Dr. David Vaux - University of Oxford, UK
|
刊名字顺( Alphabetical List of Journals):
返回页首 